Recombinant Human Secretory phospholipase A2 receptor (PLA2R1), partial

^{In
Stock}

中文名稱：

Recombinant Human Secretory phospholipase A2 receptor (PLA2R1), partial
品名簡稱：

Recombinant Human PLA2R1 protein, partial
貨號：

CSB-EP623780HUc7
說明書：

MSDS Datasheet
規格：

￥1344
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

純度：

Greater than 95% as determined by SDS-PAGE.
生物活性：

Not Test
基因名：

PLA2R1
Uniprot No.：

Q13018
種屬：

Homo sapiens (Human)
蛋白長度：

Partial
來源：

E.coli
分子量：

22.4 kDa
表達區域：

395-530aa
氨基酸序列

EEKTWHEALRSCQADNSALIDITSLAEVEFLVTLLGDENASETWIGLSSNKIPVSFEWSNDSSVIFTNWHTLEPHIFPNRSQLCVSAEQSEGHWKVKNCEERLFYICKKAGHVLSDAESGCQEGWERHGGFCYKID
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標簽：

C-terminal 6xHis-tagged
產品提供形式：

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
復溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項：

Repeated freezing and thawing is not recommended. Store working aliquots at 4℃ for up to one week.
Datasheet & COA：

Please contact us to get it.

產品評價

靶點詳情

功能：

Receptor for secretory phospholipase A2 (sPLA2). Acts as a receptor for phospholipase sPLA2-IB/PLA2G1B but not sPLA2-IIA/PLA2G2A. Also able to bind to snake PA2-like toxins. Although its precise function remains unclear, binding of sPLA2 to its receptor participates in both positive and negative regulation of sPLA2 functions as well as clearance of sPLA2. Binding of sPLA2-IB/PLA2G1B induces various effects depending on the cell type, such as activation of the mitogen-activated protein kinase (MAPK) cascade to induce cell proliferation, the production of lipid mediators, selective release of arachidonic acid in bone marrow-derived mast cells. In neutrophils, binding of sPLA2-IB/PLA2G1B can activate p38 MAPK to stimulate elastase release and cell adhesion. May be involved in responses in proinflammatory cytokine productions during endotoxic shock. Also has endocytic properties and rapidly internalizes sPLA2 ligands, which is particularly important for the clearance of extracellular sPLA2s to protect their potent enzymatic activities. The soluble secretory phospholipase A2 receptor form is circulating and acts as a negative regulator of sPLA2 functions by blocking the biological functions of sPLA2-IB/PLA2G1B. In podocytes, binding of sPLA2-IB/PLA2G1B can regulate podocyte survival and glomerular homeostasis.
基因功能參考文獻：
1. Compared with non-PLA2R-associated IMN patients in our cohort, PLA2R-associated IMN patients presented with more severe proteinuria and lower remission rates after treatment, with no distinct histological differences. PMID: 30032157
2. Suggest strong genetic association between nonsynonymous SNP rs35771982 (p.His300Asp) within PLA2R1 and idiopathic membranous nephropathy. PMID: 28849274
3. We propose a revised clinical workup flow for patients with MN that recommends assessment of kidney biopsy for PLA2R1 and THSD7A antigen expression, screening for circulating anti-podocytes antibodies, and assessment for secondary causes, especially cancer, in patients with THSD7A antibodies PMID: 29511687
4. Five SNPs around the PLA2R1 gene were significantly associated with idiopathic membranous nephropathy. PMID: 27934873
5. Several risk alleles related to the PLA2R1 gene and within the HLA loci have been identified, whereas epitope spreading of PLA2R may predict treatment response. More recently, thrombospondin type 1 domain-containing 7A (THSD7A) antibodies have been discovered in primary membranous nephropathy . PMID: 28904948
6. PLA2R may play a role in some adolescent and preteen idiopathic membranous nephropathy patients but may be less frequently associated with idiopathic membranous nephropathy during childhood PMID: 27921164
7. Anti-M-type phospholipase A2 receptor (anti-PLA2R) and anti-THSD7A (thrombospondin type-1 domain-containing 7A) were detected only in membranous neurophathy (MN) patient sera and not in controls. PMID: 27634909
8. The frameshift mutation detected in the current study would result in premature stops of amino acid synthesis in PLA2R1 and SRPK1 proteins and hence resembles a typical inactivating mutation. PMID: 28212809
9. Single-nucleotide polymorphism in PLA2R1 gene is associated with primary membranous nephropathy. PMID: 26673907
10. blocking the ERRalpha-controlled mitochondrial program largely inhibits the PLA2R1-induced tumor-suppressive response. Together, our data document ERRalpha and its mitochondrial program as downstream effectors of the PLA2R1-JAK2 pathway leading to oncosuppression. PMID: 27041564
11. Assessment of PLA2R autoimmunity is essential for patient management. Combination of PLA2R-Ab and PLA2R-Ag increases diagnosis sensitivity. PLA2R-Ab titer is a biomarker of disease severity at initial assessment, and the kinetics of the antibody are significantly correlated to disease evolution. PMID: 28257452
12. analysis of Japanese patients reveals that anti-PLA2R antibodies are present in idiopathic membranous nephropathy but not in secondary membranous nephropathy PMID: 27355365
13. Retrospective study to compare the value of serum anti-PLA2R antibody and glomerular PLA2R deposition in reflecting disease activity and renal function in Chinese patients with membranous nephropathy; serum anti-PLA2R antibody is more closely correlated with disease activity and renal function than glomerular PLA2R deposition. PMID: 28614271
14. PLA2R1 is increased in the airway epithelium in asthma, and serves as a regulator of airway hyperresponsiveness, airway permeability, antigen sensitization, and airway inflammation. PMID: 27448109
15. circulating anti-PLA2R antibodies are specific for primary membranous nephropathy. PMID: 26830547
16. PLA2R gene polymorphism is Associated with Increased Intima-Media Thickness of the Carotid Artery. PMID: 27025682
17. Report both serum and kidney levels of PLA2R1 autoantibody in idiopathic membranous nephropathy. PMID: 26369693
18. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. PMID: 26854647
19. genetic polymorphism is associated with systemic lupus erythematosus and lupus nephritis in a Chinese patients PMID: 26645973
20. Accordingly, PLA2R ABs assay seems to be promising tool not only to diagnose MN but also to predict the course of the disease and could open the way to personalize therapy. [review] PMID: 26576418
21. PLA2R1 expression in breast cancer cells is controlled by DNA methylation and histone modifications PMID: 26672991
22. Assessments of both serum PLA2R antibodies and PLA2R antigen in glomeruli were more sensitive for the diagnosis of PLA2R-related membranous nephropathy PMID: 25492250
23. Data indicate that enhanced granular expression of phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) was detected in 9.1% and 52.7%, respectively, of the patients with idiopathic membranous nephropathy (MN). PMID: 26393352
24. Anti-PLA2R antibodies were found in Japanese patients with idiopathic membranous nephropathy; however, the prevalence was lower than that of any other Asian country. PMID: 25412738
25. Suggest that PLA2R has a contributory role in the pathogenesis of paediatric idiopathic membranous nephropathy. PMID: 26194981
26. Renal biopsy PLA2R positivity was common in idiopathic membranous nephropathy (MN) and HBV-MN but rare in lupus-associated MN, and it was closely associated with serum PLA2R-Ab production. PMID: 26087695
27. Case Report: PLA2R positive membranous nephropathy in kidney transplant recipient with both IgA nephropathy and HCV infection long after kidney transplant from identical twin. PMID: 26031599
28. The detection and measurement of PLA2R-AB in idiopathic membranous nephropathy patients may be important tool in monitoring of the disease and efficacy of the treatment. PMID: 25953939
29. serological anti-PLA2R testing has diagnostic value for differentiating iMN from sMN, but it must be interpreted in context with patient clinical characteristics (degree of proteinuria, immunosuppressive treatment, time of detection). PMID: 25740009
30. Demonstrate pretransplantation circulating anti-PLA2R antibodies in a cohort of renal transplant recipients who prospectively developed recurrent disease. PMID: 25675198
31. The sPLA2 IB-PLA2R interaction stimulated podocyte apoptosis through activating ERK1/2 and cPLA2alpha and through increasing the podocyte AA content PMID: 25335547
32. Studies indicate that phospholipase A2 receptor 1 (PLA2R1) may act as a clearance or signaling receptor for secreted phospholipase A2 (sPLA2s). PMID: 25230085
33. An important role of PLA2R1 in controlling cancer cell death by influencing mitochondrial biology. PMID: 23994771
34. Data show there was strong epistasis between HLA-DQA1 single nucleotide polymorphism rs2187668 and the phospholipase A2 receptor 1 (PLA2R1) variant rs35771982. PMID: 25187357
35. Study showed that CTLD1-2 as well as the FNII domain of PLA2R were responsible for binding to collagen I and collagen-dependent migration in both mouse and human PLA2R. PMID: 25724334
36. Data show loss of VHL, stabilization of HIF-2alpha and increased c-MYC activity, binding and transcriptional repression, through induction of PLA2R1 DNA methylation closed to PLA2R1 transcriptional start site, results in decreased PLA2R1 transcription. PMID: 24657971
37. 15 of 154 patients with idiopathic membranous nephropathy had circulating autoantibodies to THSD7A but not to PLA2R1, a finding that suggests a distinct subgroup of patients with this condition. PMID: 25394321
38. This review compiles recent data demonstrating an unexpected tumor suppressive role of PLA2R1 and outlines the future work needed to improve our knowledge of the functions of this gene in cancer.[review] PMID: 24667060
39. Suggest HLA-DQA1 and PLA2R1 polymorphisms can predict idiopathic membranous nephropathy response to immunosuppressors and disease progression. PMID: 24262501
40. PLA2R1 plays a role in cancer as a tumor gene suppressor and is the major target antigen of auto-immune antibodies involved in idiopathic membranous nephropathy, a severe human kidney disease.[review] PMID: 24939538
41. We conclude that a decrease in PLA2R antibody level is associated with a decrease of proteinuria in patients with primary membranous nephropathy. PMID: 24610926
42. PLA2R staining sensitivity is much lower in the pediatric than the adult primary membranous glomerulopathy population, suggesting a more diverse and currently incompletely described set of etiologies for this disease in this group. PMID: 23903693
43. anti-PLA2R in serum of patients with idiopathic membranous nephropathy was confirmed as a reliable diagnostic marker. PMID: 24779214
44. The CC genotype and C allele at rs35771982 in PLA2R gene are associated with susceptibility to IMN in Chinese Hans. PMID: 24327152
45. We present the largest case series to date examining PLA2R1 involvement in membranous glomerulopathy PMID: 23196797
46. High levels of PLA2R antibodies are linked with active disease and a higher risk of declining renal function during follow-up in idiopathic membranous nephropathy. PMID: 23364522
47. the interaction between PLA2R1 and HLA-DQA1 risk alleles associates with the development of idiopathic membranous nephropathy in the Chinese population. PMID: 23813219
48. rare variants in the coding sequence of PLA2R1, including splice sites, are unlikely to explain the pathogenesis of idiopathic membranous nephropathy. PMID: 23431073
49. Data show that the genotyping technique of single nucleotide polymorphisms (SNPs) rs2187668 and rs4664308 within HLA-DQA1 and PLA2R1 is valuable for assessing susceptibility to idiopathic membranous nephropathy (IMN). PMID: 23194743
50. Increased staining for PLA2R in glomeruli of renal biopsies tightly correlates with the presence of PLA2R autoantibodies in the serum and this may help discriminate between primary and secondary membranous nephropathy. PMID: 22673885
顯示更多

收起更多
亞細胞定位：

Cell membrane; Single-pass type I membrane protein.; [Soluble secretory phospholipase A2 receptor]: Secreted.; [Isoform 2]: Secreted.
組織特異性：

Expressed in podocytes (at protein level). Present in lung macrophage (at protein level). Highly expressed in kidney. Also expressed in pancreas, amnion, choriodecidua and placenta. Isoform 2 is expressed at much lower level.
數據庫鏈接：

HGNC: 9042

OMIM: 604939

KEGG: hsa:22925

STRING: 9606.ENSP00000283243

UniGene: Hs.410477